Entry

D12014                      Drug

Name

Sotrovimab (USAN);
Sotrovimab (genetical recombination) (JAN);
Xevudy (TN)

Formula

C6492H10060N1744O2038S40

Exact mass

146340.5997

Mol weight

146430.4028

Sequence

(Heavy chain)
QVQLVQSGAE VKKPGASVKV SCKASGYPFT SYGISWVRQA PGQGLEWMGW ISTYQGNTNY
AQKFQGRVTM TTDTSTTTGY MELRRLRSDD TAVYYCARDY TRGAWFGESL IGGFDNWGQG
TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF
PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP
APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT
LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL
TVDKSRWQQG NVFSCSVLHE ALHSHYTQKS LSLSPGK
(Light chain)
EIVLTQSPGT LSLSPGERAT LSCRASQTVS STSLAWYQQK PGQAPRLLIY GASSRATGIP
DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QHDTSLTFGG GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H154-H210, H230-L214, H236-H'236, H239-H'239, H271-H331, H377-H435, H'22-H'96, H'154-H'210, H'230-L'214, H'271-H'331, H'377-H'435, L23-L89, L134-L194, L'23-L'89, L'134-L'194)

Type

Peptide

Class

Antiviral
DG03174 Anti-SARS-CoV-2 agent

Remark

Therapeutic category:

6250

Product:

D12014<JP>

Efficacy

Antiviral

Disease

COVID-19 [DS:H02398]

Comment

Monoclonal antibody

Target

SARS-CoV-2 spike glycoprotein [KO:K24152]

Pathway

ko03230

Viral genome structure

ko05171

Coronavirus disease - COVID-19

Brite

Therapeutic category of drugs in Japan [BR:br08301]
6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D12014  Sotrovimab (USAN); Sotrovimab (genetical recombination) (JAN)
Drug groups [BR:br08330]
Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12014  Sotrovimab
Drug classes [BR:br08332]
Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12014  Sotrovimab
Antimicrobials [BR:br08307]
Antivirals
  Entry, fusion or uncoating inhibitor
   Coronavirus spike protein
    D12014  Sotrovimab (USAN) <JP>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D12014
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D12014
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D12014
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D12014

Other DBs

CAS:	2423014-07-5